

HEADACHE MEDICINE: THE FUTURE – NEW MEDS ON THE HORIZON

Rashmi B. Halker Singh MD FAHS FAAN Director, Headache Medicine Fellowship Program Associate Professor of Neurology Mayo Clinic Scottsdale, AZ

DISCLOSURES


Research: Amgen

Editorial services: *Current Neurology and Neuroscience Reports* (Headache Section Editor), *Headache Journal* (Online & Social Media Editor, Deputy Editor)

OBJECTIVES


- 1. Identify treatment gaps with traditional therapies
- 2. Review controlled and real-world evidence on recently approved treatments for migraine
- 3. Discuss the clinical considerations when using the new treatments for migraine in clinical practice
- 4. Discuss updates in our understanding of management of migraine during pregnancy

MIGRAINE IS HIGHLY PREVALENT



Institute for Health Metrics and Evaluation. Global Burden of Disease 2016. Available from http://www.healthdata.org/gbd/data. Accessed September 15, 2017. Slide courtesy of American Headache Society Next Gen Program

ASSESSING BARRIERS TO CARE IN MIGRAINE



Consulters were patients who had seen a doctor in the past year. Preventive treatment is needed for chronic migraine. *AMPP study. [†]CaMEO study. [‡]Migraine Disability Assessment Scale (MIDAS) grade >II (mild or greater). AMPP, American Migraine Prevalence and Prevention; CaMEO, Chronic Migraine Epidemiology and Outcomes.

1. Lipton RB et al. *Headache*. 2013;53:81–92. 2. Dodick DW et al. *Headache*. 2016;56:821–834.

Slide courtesy of American Headache Society Next Gen Program

WHAT ARE THE DRIVING FORCES FOR NEW MIGRAINE TREATMENTS?

Prevalence and burden


- 15.9% of adults, 21% of women, 10.7% of men¹
- 2nd leading cause of YLD worldwide²
- Leading cause of YLD in people 15-49²

Need for new treatments

- Lack of tolerability
 - 80% discontinue oral preventive at 12 months³
- Limited efficacy (40-50%)³
- Triptans used by only 14-18% of people with migraine⁴
- Lack of options for people with certain comorbidities
 - >20% of people with migraine have CV contraindication to triptan⁵
 - An additional 25% have at least 2 CV risk factors identified as warnings/precautions to triptans⁵


Burch et al Headache 2021; 2. GBD 2016, Lancet 2017; 3. Hepp et al Cephalalgia 2017; 4. Lipton et al Headache 2018;
 Dodick et al J Prim Care Comm Health 2020

Anti-CGRP Monoclonal Antibodies






Dodick DW. Cephalalgia. 2019







Clinical Trials: Effectiveness of CGRP mAbs



Saper J, et al. AAN 2018. Abstract S20; b. Goadsby PJ, et al. *Headache*. 2017;57(Suppl 3):128; c. Stauffer VL, et al. *JAMA Neurol*. 2018.; Skljarevski V, et al. *Cephalagia*. 2018.. Dodick DW. *JAMA*. 2018;319:1999-2008.



Stauffer VL, et al. JAMA Neurol; 2018Skljarevski V, et al. Cephalalgia. 2018. Bigal ME, et al. Lancet Neurol. 2015;14:1081-1090; Smith J, et al. Headache. 2017; 57 (Suppl 1):130. Abstract IOR06.




>50% Responder Rates with CGRP mAbs

a. Smith J, et al. Headache. 2017;57 Suppl 3:130; b. Tepper S, et al. Lancet Neurol. 2017;16:425-434; c. Detke HC, et al. Cephalaigia. 2017;37:338; d. Silberstein SD, et al. N Engl J Med. 2017;37:2113-2122.

Side effects seen in clinical trials

- Compared to placebo:
 - No difference in overall and serious adverse events compared to placebo
 - No difference in discontinuation of treatment due to AEs 2.5%
- Caution: hypersensitivity (allergic/immune) and injection site reactions
- Constipation (erenumab; 1-3%)



VIEW

Efficacy and safety of calcitonin-generelated peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis



Cephalalgia

019, Vol. 39(9) 1164-1175

© International Headache Society 20 Article reuse guidelines:

sagepub.com/journals-permission: DOI: 10.1177/0333102419829003

journals.sagepub.com/home/ce

Safety and tolerability of calcitonin-generelated peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials

Hong Deng, Gai-gai Li^{*}, Hao Nie, Yang-yang Feng, Guang-yu Guo, Wen-liang Guo and Zhou-ping Tang^{*}

REAL-WORLD EXPERIENCE WITH MABS: WHAT CAN PATIENTS EXPECT?


- Similar efficacy
 - Even if other treatments have failed
 - Even with medication overuse
 - Even with significant comorbidity
- Onset can be within first week or first day
- Can safely and effectively combine CGRP mAbs with onabotulinumtoxinA & gepants
- Efficacy can increase over time
- If one CGRP mAb does is ineffective or not tolerated, can try another

Silberstein et al 2020; Diener et al 2020; Dodick et al 2020; Mulleners et al 2020; Kanaan et al 2020; Robblee et al 2020; Alex et al 2020; Saely et al 2021; Blumenfeld et al AAN 2021; Blumenfeld et al AAN 2021

- Higher rate of known AEs (ie constipation 13-43% with erenumab)
- New AEs (dizziness, fatigue, cramps, joint pain, fatigue, nausea, alopecia, worsening headache)
- Early wearing off (before next dose, over time)
- Women must wait 5 months from last dose to conceive
- New FDA warnings: hypertension & erenumab (majority within 1st week of 1st dose), constipation & erenumab
- All CGRP mAbs are ineffective for some

CGRP SMALL MOLECULE DRUGS (GEPANTS)





Guidelines Acute Migraine Treatment

Level A

All triptans

DHE NS

NSAIDs: Diclofenac, aspirin, naproxen, ibuprofen

Acetaminophen/aspirin/caffein e 500/500/130 mg

Acetaminophen 1000 mg (for non-incapacitating attacks)

Level B

Anti-emetics: IV Metoclopramide & Prochlorperazine

Anti-dopamine: IV Chlorpromazine & Droperidol IV

Ergots: IM/IV DHE

NSAIDS: Ketorolac

Marmura MJ et al Headache 2015

NEXT GENERATION ORAL ACUTE TREATMENTS

FDA approved for acute treatment

- Gepants
 - Ubrogepant 50mg or 100mg during attack, repeat once as needed
 - Rimegepant 75mg ODT once during attack
- Ditans
 - Lasmiditan 50mg, 100mg, 200mg once during attack

Consider in those who have (any of below)

- Found 2 triptans ineffective/had side effects
- Contraindications to standard therapy

Dodick DW. NEJM 2019; Lipton RB. JAMA 2019; Lipton RB. NEJM 2019; Croop R. Lancet. 2019; Kuca B. Neurology 2018; Goadsby PJ. Brain 2019; Digre K Headache 2018; Ailani J Headache 2021

Ubrogepant

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Ubrogepant for the Treatment of Migraine

David W. Dodick, M.D., Richard B. Lipton, M.D., Jessica Ailani, M.D., Kaifeng Lu, Ph.D., Michelle Finnegan, M.P.H., Joel M. Trugman, M.D., and Armin Szegedi, M.D.

JAMA | Original Investigation

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine The ACHIEVE II Randomized Clinical Trial

Richard B. Lipton, MD; David W. Dodick, MD; Jessica Ailani, MD; Kaifeng Lu, PhD; Michelle Finnegan, MPH; Armin Szegedi, MD; Joel M. Trugman, MD

- Free of pain @ 2 hours
 - 19-22% (mod/severe pain)
 - 39-43% (mild pain)
- Relief of pain @ 2 hours
 - 61-63%
- Nausea, dizziness (~2%)

Rimegepant

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Robert Croop, Peter J Goadsby, David A Stock, Charles M Conway, Micaela Forshaw, Elyse G Stock, Vladimir Coric, Richard B Lipton

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton, M.D., Robert Croop, M.D., Elyse G. Stock, M.D., David A. Stock, Ph.D., Beth A. Morris, B.A., Marianne Frost, M.A., Gene M. Dubowchik, Ph.D., Charles M. Conway, Ph.D., Vladimir Coric, M.D., and Peter J. Goadsby, M.D., Ph.D.

- Free of pain @ 2 hours
 - 20-21% (treating moderate or severe pain)
- Relief of pain @ 2 hours
 - 58-59%
- Nausea (2%), dizziness (1%)

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Robert Croop, Richard B Lipton, David Kudrow, David A Stock, Lisa Kamen, Charles M Conway, Elyse G Stock, Vladimir Coric, Peter J Goadsby

_

	MMD reduction	Responder rate (<u>></u> 50%)
Placebo (n=347)	3.5	41.5
75mg (n=348)	4.3*	49.1**

*	p<0.01
**	p<0.04

*

€

	TRAE	Dropout due to AE	SAE	Nausea
Placebo (n=347)	8.6	1.1	1.1	0.8
75mg (n=348)	10.8	1.9	0.8	2.7

Atogepant: Small molecule oral drug for prevention

Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial


Peter J Goadsby, David W Dodick, Jessica Ailani, Joel M Trugman, Michelle Finnegan, Kaifeng Lu, Armin Szegedi

52-62% were responders (> 50% reduction in migraine days per month)

Side effects: nausea (3-9%), constipation (1-4%); fatigue (1-7%), decreased appetite (3-4%)

Lancet Neuro 2020;19:727-737

Atogepant: Time Course of Efficacy (Modified Intention-to-Treat Population)



Ailani J et al. N Engl J Med 2021;385:695-706

Gepants: Summary

Effective for acute and preventive treatment First acute treatment not at risk for MOH More likely/effective if used when pain is mild Effective in those for whom triptans failed Generally well tolerated (nausea, constipation, fatigue)


Not contraindicated in patients with CV disease

Original Article

Cephalalgia

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache 00) I-1 © International Headache Society 2020 COC Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177033102420938652 journals.sagepub.com/home/cep ©SAGE

Edita Navratilova¹ (0), Sasan Behravesh², Janice Oyarzo², David W Dodick³, Pradeep Banerjee⁴ and Frank Porreca^{1,2}



Lipton RB, et al. Neurology. 2020;94(15 Suppl): 4726.

Individualizing the Choice of Treatment with Gepants

Ubrogepant (acute treatment)

• For patients who might want the option of a second dose, or different dosing options


Rimegepant (acute treatment/EM prevention)

- For patients who want the convenience of an oral dissolving tablet for acute treatment
- For patients with episodic migraine who want to try CGRP preventive therapy, but want to try something with a shorter half-life than mAbs


Atogepant (EM prevention)


- For patients with episodic migraine who want to try CGRP preventive therapy, but want to try something with a shorter half-life than mAbs
- For patients who might want an option of different doses to consider


Historical Drug Target For Acute Migraine Treatment Cerebral Blood Vessels



Lasmiditan: Selective 5HT-1F receptor agonist








Central 5HT-1F Receptor Distribution and Side Effect Profile

SAMURAI (First Dose)			SPARTAN (First Dose)				
TEAEsª	L 200 mg (n=609)	L 100 mg (n=630)	PBO (n=617)	L 200 mg (n=649)	L 100 mg (n=635)	L 50 mg (n=654)	PBO (n=645)
≥1 TEAEs	42.2%	36.3%	16.0%	39.0%	36.1%	25.4%	11.6%
Dizziness	16.3%	12.5%	3.4%	18.0%	18.1%	8.6%	2.5%
Paresthesia	7.9%	5.7%	2.1%	6.6%	5.8%	2.4%	0.9%
Somnolence	5.4%	5.7%	2.3%	6.5%	4.6%	5.4%	2.0%
Fatigue	3.1%	4.1%	0.3%	4.8%	4.1%	2.8%	0.9%
Nausea	5.3%	3.0%	1.9%	2.6%	3.3%	2.8%	1.2%
Lethargy	2.5%	1.9%	0.3%	2.2%	1.3%	1.2%	0.2%



RESEARCH ARTICLE


WILEY


Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls

Eric M. Pearlman¹ | Darren Wilbraham¹ | Ellen B. Dennehy^{1,2} | Paul H. Berg¹ | Max Tsai¹ | Erin G. Doty¹ | Gary G. Kay³

Vila-Pueyo. Neurotherapeutics (2018) 15:291–303,

OTHER TRIGEMINAL SENSORY TARGETS






JAMA | Original Investigation

Acute Treatments for Episodic Migraine in Adults A Systematic Review and Meta-analysis

Juliana H. VanderPluym, MD; Rashmi B. Halker Singh, MD; Meritxell Urtecho, MD; Allison S. Morrow, BA; Tarek Nayfeh, MD; Victor D. Torres Roldan, MD; Magdoleen H. Farah, MBBS; Bashar Hasan, MD; Samer Saadi, MD; Sahrish Shah, MBBS; Rami Abd-Rabu, MBBS; Lubna Daraz, PhD; Larry J. Prokop, MLS; Mohammad Hassan Murad, MD, MPH; Zhen Wang, PhD

JAMA. 2021;325(23):2357-2369. doi:10.1001/jama.2021.7939

- Use of triptans, NSAIDs, acetaminophen, DHE, CGRP antagonists, lasmiditan, & some nonpharm treatments were associated with improved pain and function
- The evidence for opioids in the acute treatment of migraine is limited



MOH: UPDATES IN UNDERSTANDING FROM THE MOTS TRIAL

- Methods: 720 participants with migraine & MOH randomized to 1) preventive treatment only or 2) preventive treatment & switching to alternative acute treatment (max 2 days/week)
- Primary outcome: Migraine preventive medication without switching of the overused medication was not inferior to preventive medication with switching for moderate-tosevere headache day frequency during weeks 9-12
- Secondary outcome: Switching group had reduced their consumption of medication by 52% (vs 32% in the non-switching group) at weeks 9-12
- Conclusion: For patients with CM and medication overuse, the efficacy of starting or optimizing preventive medication is *not dependent* on whether patients first reduce their use of acute medication



Copyright © 2022 American Academy of Neurology. Unauthorized reproduction of this article is prohibited

Ask about CONTRACEPTION AND PREGNANCY PLANS...





Many patients are women of childbearing potential - these decisions will impact treatment choices.



acal Education and Research | slide-28

EFFECT OF MIGRAINE ON PREGNANCY PLANNING: INSIGHTS FROM THE AMERICAN REGISTRY FOR MIGRAINE RESEARCH (ARMR) DATABASE

- Almost 20% of women with migraine in the ARMR database attested to pregnancy avoidance because of migraine
- Those who indicated intent to avoid pregnancy were:
 - predominantly young
 - are more likely to have menstrual migraine
 - are more likely to have never been pregnant since the onset of migraine
- Migraine usually improves during pregnancy, especially in patients who have migraine without aura, migraine that started with menarche, or menstrual migraine.
 - About 1/2 to 3/4 of those with migraine have a marked improvement in migraine during pregnancy, with a significant reduction in attack frequency and intensity, especially during second and third trimesters
- Education is important!

Ishii R et al Mayo Clinic Proc 2020 Halker Singh RB & Sirven JI Mayo Clinic Proc 2020 MANAGEMENT OF PRIMARY HEADACHES DURING PREGNANCY, POSTPARTUM, AND BREASTFEEDING: A SYSTEMATIC REVIEW

- Methods: 8549 citations for studies and 2788 citations for SRs.
 Sixteen studies (mostly high risk of bias) comprising 14,185
 patients (total) and 26 SRs met the criteria
- *Prevention:* calcium channel blockers and antihistamines may not be associated with fetal/child adverse effects
- Acute treatment: combination metoclopramide and diphenhydramine may be more effective than codeine. Triptans and low-dose aspirin may not be associated with fetal/child adverse effects; notable finding that triptan use for migraine during pregnancy seems to have low risk of adverse effects
- Nonpharm: 6 studies on nonpharmacologic approaches for acute treatment of headache (no preventive studies) – not enough to make conclusions on benefits/harms

Saldanha IJ et al Headache 2021 Hamilton KT Headache 2021

Conclusions

- Advances in our understanding of the molecular biology of migraine has led to:
 - The first migraine-specific therapy developed, approved, and available for prevention
 - Two new acute drug classes since the triptans emerged 30 years ago
 - A move away from drugs that constrict blood vessels to those which act on peripheral trigeminal nerve and/or central brain targets
 - The first acute drug class demonstrated not to produce medication overuse headache ("rebound")
 - Very important expansion in the treatment options for many patients







That's why it's essential that you have access to accurate, timely information on migraine and headache disorders. **First Contact – Headache in Primary Care** provides free educational resources to help you identify and treat migraine.



Flowchart



Learn more and explore our resources here:



Articles